1616288-89-1

Usage

Derivative of pyridine

2-(((2-(benzyloxy)-4,6-dimethylpyridin-3-yl)methyl)amino)ethanol is derived from pyridine A heterocyclic aromatic compound with a six-membered ring structure, which consists of five carbon atoms and one nitrogen atom.

Contains an ethanolamine group

The compound has an ethanolamine group (C2H7NO) An organic compound that consists of an amino group (-NH2) and an ethanol group (C2H5OH), which can potentially form hydrogen bonds with biological molecules.

Potential applications in pharmaceuticals

The compound has potential applications in the pharmaceutical industry due to the presence of both a pyridine ring and an ethanolamine group, which can interact with biological molecules.

Presence of benzyloxy group

The compound contains a benzyloxy group (C6H5CH2O-) A functional group derived from benzyl alcohol, which can enhance the compound's solubility and potentially be used in drug formulations.

Promising candidate for further study and drug development

The chemical structure and properties of 2-(((2-(benzyloxy)-4,6-dimethylpyridin-3-yl)methyl)amino)ethanol make it a promising candidate for further research and potential drug development, due to its unique combination of functional groups and potential interactions with biological molecules.

Upstream product

• 721959-71-3 2-(benzyloxy)-4,6-dimethylpyridine-3-carbaldehyde 
• 100-44-7 benzyl chloride 
• 141-43-5 ethanolamine 
• 53475-53-9 2-(benzyloxy)-4,6-dimethylpyridine-3-carbonitrile 
• 769-28-8 2-hydroxy-4,6-dimethyl-3-carbonitrile 

Downstream Products

• 1616290-23-3 ethyl 2-(2-(((2-(benzyloxy)-4,6-dimethylpyridin-3-yl)methyl)((tert-butoxy)carbonyl)amino)ethoxy)-3-bromo-6-methyl-5-((methylsulfonyl)oxy)benzoate 
• 1616290-25-5 ethyl 2-(2-(((2-(benzyloxy)-4,6-dimethylpyridin-3-yl)methyl)amino)ethoxy)-3-bromo-6-methyl-5-((methylsulfonyl)oxy)benzoate 
• 1616290-27-7 4-((2-(benzyloxy)-4,6-dimethylpyridin-3-yl)methyl)-9-bromo-7-isopropoxy-6-methyl-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one 
• 1616290-50-6 4-{[2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methyl}-6-methyl-9-[2-(methylamino)pyrimidin-5-yl]-7-(propan-2-yloxy)-3,4-dihydro-1,4-benzoxazepin-5(2H)-one 
• 1616288-91-5 tert-butyl ((2-(benzyloxy)-4,6-dimethylpyridin-3-yl)methyl)(2-hydroxyethyl)carbamate 
• 1616290-35-7 N-{[2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methyl}-2-chloro-6-fluoro-N-(2-hydroxyethyl)-3-methoxybenzamide 
• 1616290-17-5 4-{[2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methyl}-7-ethoxy-6-methyl-3,4-dihydro-1,4-benzoxazepin-5(2H)-one 
• 1616290-37-9 4-((2-benzyloxy-4,6-dimethylpyridin-3-yl)methyl)-6-chloro-7-methoxy-3,4-dihydrobenzo[f ][1,4]oxazepin-5(2H)-one 
• 1616290-15-3 N-{[2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methyl}-3-ethoxy-6-hydroxy-N-(2-hydroxyethyl)-2-methylbenzamide 

Relevant academic research and scientific papers

Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors

A new enhancer of zeste homolog 2 (EZH2) inhibitor series comprising a substituted phenyl ring joined to a dimethylpyridone moiety via an amide linkage has been designed. A preferential amide torsion that improved the binding properties of the compounds was identified for this series via computational analysis. Cyclization of the amide linker resulted in a six-membered lactam analogue, compound 18. This transformation significantly improved the ligand efficiency/potency of the cyclized compound relative to its acyclic analogue. Additional optimization of the lactam-containing EZH2 inhibitors focused on lipophilic efficiency (LipE) improvement, which provided compound 31. Compound 31 displayed improved LipE and on-target potency in both biochemical and cellular readouts relative to compound 18. Inhibitor 31 also displayed robust in vivo antitumor growth activity and dose-dependent de-repression of EZH2 target genes.

ARYL AND HETEROARYL FUSED LACTAMS

This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.